Hedge Fund - Perceptive Advisors

*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing...

One would think that a hepatitis B vaccine with 100% efficacy, negligible safety issues, and mountains of clinical data already supporting it would be valued at a little bit more than $70 million.

Joseph Edelman's Perceptive Advisors is a fund that has an equity portfolio worth $1.44 billion as of the end of June, with over 80% of it being invested in healthcare stocks.

According to a recent 13G filing with the US Securities and Exchange Commission, Joseph Edelman's Perceptive Advisors has increased its stake in Versartis Inc.

Bloomberg recently came out with its list of best performing hedge funds of 2015 and the fund that managed to beat all its rivals and emerge at the top of the list was biotech-focused hedge fund Perceptive...

With the latest round of 13F filings gathering pace, hedge fund managers are busy preparing to deluge us with the contents of their portfolios, which powers our market-beating small-cap strategy.

Biotech Guru Joseph Edelman's Perceptive Advisors is known for its long-short investment approach that focuses on biotech stocks.

The health care sector has appreciated by nearly 30% over the past year. We decided to take a look at three companies that two health care-focused funds, namely James A.

Perceptive Advisors, managed by Joseph Edelman, is bullish on Amicus Therapeutics Inc. (NASDAQ:FOLD). In a new filing with the U.S.